Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?

Autores de IIS La Fe

• Rosa Cámara Gómez

  Autor

Participantes ajenos a IIS La Fe

• Martínez-López S
• García-Martínez A
• Torregrosa-Quesada ME
• López-Muñoz B
• Fajardo C
• Lamas C
• Picó A

Grupos

• Unidad Mixta de Investigación en Endocrinología, Nutrición y Dietética clínica

  Leader

  Juan Francisco Merino Torres

Abstract

Silent somatotroph tumors (sSTs) are pituitary neuroendocrine tumors (PitNETs) which do not give rise to the clinical syndrome of acromegaly. Differently to their functioning counterparts, the adjuvant medical treatment with somatostatin analogues (SSAs) or dopamine receptors agonists (DAs) has been scarcely addressed in these tumors. As preliminary results of an ongoing research on silencing mechanisms involved in the pathogenesis of sSTs, we have characterized by qRT-PCR the expression of SSTRs and DRDs in a large series of 18 silent and 68 functioning STs. Although the expression of SSTR2 and SSTR5 was lower in sSTs than in functioning ones, we found a negative correlation between SSTR2 and the tumor size of the sSTs. Additionally, levels of expression of DRD2 were similar between the two subtypes suggesting a possible basis for the treatment of these tumors with SSAs and DAs.

Keywords

• Acromegaly, Dopamine receptor (DRD), Pituitary neuroendocrine tumor (PitNET), Silent somatotroph tumor (sST), Somatostatin analogues (SSAs), Somatostatin receptor (SSTR)